Evidence map›Paper›PMID 38393537›Full record

ArticleClinical journal of gastroenterology2024

Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome.

Akio Matsumoto, Yoshifumi Shimada, Mae Nakano, Hikaru Ozeki, Daisuke Yamai, Masaki Murata, Fumio Ishizaki, Hiromi Nyuzuki, Takeshi Ikeuchi, Toshifumi Wakai

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Akio MatsumotoDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan.
Yoshifumi ShimadaDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan. shimaday@med.niigata-u.ac.jp.ORCID http://orcid.org/0000-0003-0524-236X
Mae NakanoDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan.
Hikaru OzekiDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan.
Daisuke YamaiDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan.
Masaki MurataMedical Genome Center, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori, Chuo-Ku, Niigata, Japan.
Fumio IshizakiMedical Genome Center, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori, Chuo-Ku, Niigata, Japan.
Hiromi NyuzukiCenter for Medical Genetics, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori, Chuo-Ku, Niigata, Japan.
Takeshi IkeuchiCenter for Medical Genetics, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori, Chuo-Ku, Niigata, Japan.
Toshifumi WakaiDivision of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 9518510, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 44-year-old woman with Lynch syndrome was referred to our hospital for treatment of recurrence of microsatellite instability-high rectal cancer. [

Indexed as

Antibodies, Monoclonal, HumanizedColorectal Neoplasms, Hereditary NonpolyposisHydronephrosisPeritoneal NeoplasmsRectal NeoplasmsAdultAntineoplastic Agents, ImmunologicalFemaleHumansNephrostomy, PercutaneousUrinary Tract InfectionsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabConversion therapyHydronephrosisPembrolizumabPeritoneal metastasisRectal cancer

Identifiers

PMID38393537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.